TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
TransThera Sciences (Nanjing), Inc. (HKG: 2617) announced that China’s National Medical Products Administration (NMPA) formally...
HKG: 2617
TransThera Tinengotinib Cholangiocarcinoma Priority Review China
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...
TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...
TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...
TransThera Begins Phase II Tinengotinib Trial with Akeso Bispecifics for Advanced HCC
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced the first patient dose in an open‑label, multi‑center...
TransThera Sciences’ Tinengotinib Gains FDA Fast Track for mCRPC Treatment
China-headquartered TransThera Sciences (Nanjing) Inc., (HKG: 2617), which listed in Hong Kong this week, announced...